<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="by the World Health Organization on 11 March, 2020. SARS-CoV-2" exact="infection" post="in severe cases involves the host response as an"/>
 <result pre="chronic conditions, not only for those who are already receiving" exact="treatment" post="but also for those who are about to start"/>
 <result pre="also for those who are about to start a new" exact="treatment" post="to control their disease. In this article, the management"/>
 <result pre="hidradenitis suppurativa, not only for those who are already receiving" exact="treatment" post="but also for those who are about to start"/>
 <result pre="also for those who are about to start a new" exact="treatment" post="to control their disease. The hostâ€™s dysregulated and excessive"/>
 <result pre="disease progression [5]. In line with SARS and MERS, SARS-CoV-2" exact="infection" post="in severe cases involves the host response as an"/>
 <result pre="dry cough, anorexia, dyspnea, rhinorrhea, ageusia, anosmia) and confirmed by" exact="polymerase chain reaction" post="tests on nasopharyngeal and oropharyngeal swabs or sputum. There"/>
 <result pre="indications for antimalarials [15]. Corticosteroids are generally contraindicated in the" exact="treatment" post="of COVID-19 [16], but the underlying cytokine storm has"/>
 <result pre="chronic conditions, not only for those who are already receiving" exact="treatment" post="but also for those who are about to start"/>
 <result pre="also for those who are about to start a new" exact="treatment" post="to control their disease. Most recommendations from dermatology societies"/>
 <result pre="postpone immunosuppressive or biologic therapy in the event of COVID-19" exact="diagnosis" post="until the patient recovers from the infection. However, the"/>
 <result pre="from the infection. However, the decision to stop or withhold" exact="treatment" post="is left to the joint consideration of the patient"/>
 <result pre="There is no available evidence that supports discontinuation of biologic" exact="treatment" post="of psoriasis for most patients simply because of the"/>
 <result pre="psoriasis for most patients simply because of the risk of" exact="infection" post="[24]. According to the results of randomized clinical trials"/>
 <result pre="and TNFÎ± inhibitors for dermatologic patients in areas with high" exact="infection" post="rates and stopping all immunosuppressive and biological therapy when"/>
 <result pre="imply an even greater infectious risk factor than continuation of" exact="treatment" post="[29], and the use of systemic corticosteroids might contribute"/>
 <result pre="might contribute to viral replication in the event of SARS-CoV-2" exact="infection" post="[30]. Immunosuppressive medications in transplanted patients increase the risk"/>
 <result pre="transplantation, autoimmune liver disease, or chemotherapy for hepatoblastoma, despite some" exact="testing" post="positive for SARS-CoV-2, none developed clinical pulmonary disease [34]."/>
 <result pre="Tumor necrosis factor inhibitors might be effective in reducing SARS-CoV2" exact="infection" post="and the associated organ damage, by decreasing TNF-Î±-converting enzyme-dependent"/>
 <result pre="into the cell [36]. A study evaluating adalimumab in COVID-19" exact="infection" post="has recently been registered in the Chinese Clinical Trial"/>
 <result pre="the use of dupilumab, an IL-4/IL-13 inhibitor used in the" exact="treatment" post="of atopic dermatitis, to mitigate the â€œcytokine stormâ€� seen"/>
 <result pre="and Drug Administration and the European Medicines Agency for the" exact="treatment" post="of atopic dermatitis, has been predicted to reduce the"/>
 <result pre="the plasma concentration obtained with the submitted dosage for the" exact="treatment" post="of atopic dermatitis (2â€&quot;4Â mg daily), as well as"/>
 <result pre="(including psoriasis, atopic dermatitis, and hidradenitis suppurativa) can continue their" exact="treatment" post="even during the COVID-19 outbreak, preventing disease flares that"/>
 <result pre="usage. It is generally recommended to withhold immunosuppressive or biologic" exact="treatment" post="in patients with active COVID-19 infection. In patients living"/>
 <result pre="be given to the lengthening of administration intervals or temporary" exact="treatment" post="discontinuation. Comorbidities associated with psoriasis, hidradenitis suppurativa, and atopic"/>
 <result pre="worsen the prognosis of COVID-19 infection, and in these cases," exact="treatment" post="interruption and perhaps individual isolation in some circumstances deserve"/>
 <result pre="infection, and in these cases, treatment interruption and perhaps individual" exact="isolation" post="in some circumstances deserve special consideration. In the future,"/>
 <result pre="to the immunization recommendations for patients receiving immunosuppressive or biologic" exact="treatment" post="for dermatologic indications, including psoriasis, atopic dermatitis, and hidradenitis"/>
 <result pre="M, Rajnik M, Cuomo A, et al. Features, evaluation and" exact="treatment" post="coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing. 2020."/>
 <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect"/>
 <result pre="a recommendation to examine the effect of hydroxychloroquine in preventing" exact="infection" post="and progressionJ Antimicrob Chemother.202010.1093/jac/dkaa11432196083 15.KimAHJSparksJALiewJWet al.A rush to judgment?"/>
 <result pre="Intern Med202010.7326/M20-122332271869 16.ZhangWZhaoYZhangFet al.The use of anti-inflammatory drugs in the" exact="treatment" post="of people with severe coronavirus disease 2019 (COVID-19): the"/>
 <result pre="https://www.ioibd.org/ioibd-update-on-covid19-for-patients-with-crohns-disease-and-ulcerative-colitis/. Accessed 1 Apr 2020. 24.BashyamAMFeldmanSRShould patients stop their biologic" exact="treatment" post="during the COVID-19 pandemicJ Dermatolog Treat2020191210.1080/09546634.2020.1742438 25.LebwohlMRivera-OyolaRMurrellDFShould biologics for"/>
 <result pre="Dermatol.202010.1016/j.jaad.2020.03.04632224277 27.ConfortiCGiuffridaRDianzaniCet al.COVID-19 and psoriasis: is it time to limit" exact="treatment" post="with immunosuppressants? A call for actionDermatol Ther202011e1329810.1111/dth.13298 28.ShahPZampellaJGUse of"/>
 <result pre="disease 2019 (COVID-19) pandemicJ Am Acad Dermatol.202010.1016/j.jaad.2020.03.05632244021 29.FavalliEGIngegnoliFDe LuciaOet al.COVID-19" exact="infection" post="and rheumatoid arthritis: faraway, so close!Autoimmun Rev20202010252310.1016/j.autrev.2020.102523 30.RussellCDMillarJEBaillieJKClinical evidence"/>
 <result pre="faraway, so close!Autoimmun Rev20202010252310.1016/j.autrev.2020.102523 30.RussellCDMillarJEBaillieJKClinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injuryLancet20203951022347347510.1016/S0140-6736(20)30317-232043983 31.KaltsasASepkowitzKCommunity acquired respiratory and gastrointestinal"/>
 <result pre="from bench to bedside?PLoS ONE20149e8871610.1371/journal.pone.008871624551142 39.JossetLMenacheryVDGralinskiLEet al.Cell host response to" exact="infection" post="with novel human coronavirus EMC predicts potential antivirals and"/>
 <result pre="syndrome by mitigating cytokine storm. 10.31219/osf.io/hk7ep 42.RichardsonPGriffinITuckerCet al.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 43.SanchezGAMReinhardtARamseySet al.JAK1/2 inhibition with"/>
 <result pre="acute respiratory diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 43.SanchezGAMReinhardtARamseySet al.JAK1/2 inhibition with baricitinib in the" exact="treatment" post="of autoinflammatory interferonopathiesJ Clin Invest20181283041305210.1172/JCI9881429649002 44.HuiDSSystemic corticosteroid therapy may"/>
 <result pre="Med201819770070110.1164/rccm.201712-2371ED29227752 45.World Health Organization. Clinical management of severe acute respiratory" exact="infection" post="when COVID-19 is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 1 Apr 2020."/>
</results>
